Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiation and third-generation chemotherapy.

Yuhchyau Chen1, Paul Okunieff

  • 1Department of Radiation Oncology, University of Rochester Medical Center, 600 Elmwood Avenue, Box 647, Rochester, NY 14642, USA. yuhchyau_chen@urmc.rochester.edu

Hematology/Oncology Clinics of North America
|March 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

Cancer·2026
Same author

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Building Equitable Cancer Research Infrastructure: Successful Transfer of Patient-Derived Xenograft Technology to a Historically Black University.

Cancer control : journal of the Moffitt Cancer Center·2025
Same author

KDM3B Regulates Postradiation Fibrotic Responses in Prostate Stroma via N<sup>6</sup>-methyladenosine Modification of LOX.

International journal of radiation oncology, biology, physics·2025
Same author

Clinical Practice-Based Failure Modes and Root Cause Analysis of Cone Beam CT-Guided Online Adaptive Radiotherapy of the Pelvis.

Cancers·2025
Same author

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Third-generation chemotherapy agents show promise for non-small cell lung cancer (NSCLC) chemoradiation, improving tumor response but increasing toxicity. Optimal sequencing and dosing remain key challenges for better survival outcomes.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Third-generation chemotherapeutic agents demonstrate independent activity against non-small cell lung cancer (NSCLC).
  • These agents potentiate radiation effects, showing promise for combined chemoradiation therapy in locally advanced NSCLC.
  • Concurrent administration with thoracic radiation increases the risk and severity of esophagitis and pneumonitis.

Purpose of the Study:

  • To review the efficacy and toxicity of third-generation chemotherapeutic agents in combination with radiation for NSCLC.
  • To explore optimal dosing, sequencing, and scheduling strategies for chemoradiation in NSCLC.
  • To identify challenges and future directions in NSCLC chemoradiation therapy.

Main Methods:

  • Review of preclinical research and phase I/II clinical studies on third-generation chemotherapeutic agents for NSCLC.

Related Experiment Videos

  • Analysis of dose reduction requirements for concurrent chemoradiation compared to metastatic disease settings.
  • Evaluation of various dose schedules and multiagent versus single-agent chemoradiation approaches.

    • Main Results:

    • Third-generation agents improve local tumor response rates in NSCLC when combined with radiation.
    • Concurrent chemoradiation with these agents leads to increased toxicity, particularly esophagitis and pneumonitis.
    • Multiagent chemoradiation increased toxicity without improving tumor response rates compared to single-agent regimens.
    • Optimal sequencing and scheduling strategies, like pulsed low-dose paclitaxel, show potential for improved outcomes and reduced toxicity.

    Conclusions:

    • Chemoradiation with third-generation agents enhances local tumor response in NSCLC but elevates toxicity.
    • Further research is needed to determine optimal drug sequencing, dosing, and scheduling for improved survival.
    • Advanced radiotherapy techniques and novel therapeutic strategies are under investigation to minimize toxicity and enhance treatment efficacy.